These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 23446219)

  • 1. Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
    White AD; Sibley L; Dennis MJ; Gooch K; Betts G; Edwards N; Reyes-Sandoval A; Carroll MW; Williams A; Marsh PD; McShane H; Sharpe SA
    Clin Vaccine Immunol; 2013 May; 20(5):663-72. PubMed ID: 23446219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
    Manjaly Thomas ZR; Satti I; Marshall JL; Harris SA; Lopez Ramon R; Hamidi A; Minhinnick A; Riste M; Stockdale L; Lawrie AM; Vermaak S; Wilkie M; Bettinson H; McShane H
    PLoS Med; 2019 Apr; 16(4):e1002790. PubMed ID: 31039172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
    Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
    Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.
    Darrah PA; Bolton DL; Lackner AA; Kaushal D; Aye PP; Mehra S; Blanchard JL; Didier PJ; Roy CJ; Rao SS; Hokey DA; Scanga CA; Sizemore DR; Sadoff JC; Roederer M; Seder RA
    J Immunol; 2014 Aug; 193(4):1799-811. PubMed ID: 25024382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
    Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
    Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.
    Verreck FA; Vervenne RA; Kondova I; van Kralingen KW; Remarque EJ; Braskamp G; van der Werff NM; Kersbergen A; Ottenhoff TH; Heidt PJ; Gilbert SC; Gicquel B; Hill AV; Martin C; McShane H; Thomas AW
    PLoS One; 2009; 4(4):e5264. PubMed ID: 19367339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route.
    Audran R; Karoui O; Donnet L; Soumas V; Fares F; Lovis A; Noirez L; Cavassini M; Fayet-Mello A; Satti I; McShane H; Spertini F
    J Infect; 2024 Aug; 89(2):106205. PubMed ID: 38897242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults.
    Wilkie M; Satti I; Minhinnick A; Harris S; Riste M; Ramon RL; Sheehan S; Thomas ZM; Wright D; Stockdale L; Hamidi A; O'Shea MK; Dwivedi K; Behrens HM; Davenne T; Morton J; Vermaak S; Lawrie A; Moss P; McShane H
    Vaccine; 2020 Jan; 38(4):779-789. PubMed ID: 31735500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
    Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
    PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
    Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
    Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the Immunogenicity of Mycobacterium bovis BCG Delivered by Aerosol to the Lungs of Macaques.
    White AD; Sarfas C; West K; Sibley LS; Wareham AS; Clark S; Dennis MJ; Williams A; Marsh PD; Sharpe SA
    Clin Vaccine Immunol; 2015 Sep; 22(9):992-1003. PubMed ID: 26108288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.
    Hokey DA; Wachholder R; Darrah PA; Bolton DL; Barouch DH; Hill K; Dheenadhayalan V; Schwander S; Godin CS; Douoguih M; Pau MG; Seder RA; Roederer M; Sadoff JC; Sizemore D
    Hum Vaccin Immunother; 2014; 10(8):2199-210. PubMed ID: 25424923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial.
    Ndiaye BP; Thienemann F; Ota M; Landry BS; Camara M; Dièye S; Dieye TN; Esmail H; Goliath R; Huygen K; January V; Ndiaye I; Oni T; Raine M; Romano M; Satti I; Sutton S; Thiam A; Wilkinson KA; Mboup S; Wilkinson RJ; McShane H;
    Lancet Respir Med; 2015 Mar; 3(3):190-200. PubMed ID: 25726088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans.
    Jeyanathan M; Fritz DK; Afkhami S; Aguirre E; Howie KJ; Zganiacz A; Dvorkin-Gheva A; Thompson MR; Silver RF; Cusack RP; Lichty BD; O'Byrne PM; Kolb M; Medina MFC; Dolovich MB; Satia I; Gauvreau GM; Xing Z; Smaill F
    JCI Insight; 2022 Feb; 7(3):. PubMed ID: 34990408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis.
    Wang J; Thorson L; Stokes RW; Santosuosso M; Huygen K; Zganiacz A; Hitt M; Xing Z
    J Immunol; 2004 Nov; 173(10):6357-65. PubMed ID: 15528375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B.
    Dai G; Rady HF; Huang W; Shellito JE; Mason C; Ramsay AJ
    Vaccine; 2016 Dec; 34(50):6267-6275. PubMed ID: 27823900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A.
    Stylianou E; Griffiths KL; Poyntz HC; Harrington-Kandt R; Dicks MD; Stockdale L; Betts G; McShane H
    Vaccine; 2015 Nov; 33(48):6800-8. PubMed ID: 26478198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.